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Abstract
Background: Breast cancer susceptibility may be modulated partly through polymorphisms in oxidative enzymes, one of
which is myeloperoxidase (MPO). Association of the low transcription activity variant allele A in the G463A polymorphism
has been investigated for its association with breast cancer risk, considering the modifying effects of menopausal status and
antioxidant intake levels of cases and controls.
Methodology/Principal Findings: To obtain a more precise estimate of association using the odds ratio (OR), we performed
a meta-analysis of 2,975 cases and 3,427 controls from three published articles of Caucasian populations living in the United
States. Heterogeneity among studies was tested and sensitivity analysis was applied. The lower transcriptional activity AA
genotype of MPO in the pre-menopausal population showed significantly reduced risk (OR 0.56–0.57, p=0.03) in contrast to
their post-menopausal counterparts which showed non-significant increased risk (OR 1.14; p=0.34–0.36). High intake of
antioxidants (OR 0.67–0.86, p=0.04–0.05) and carotenoids (OR 0.68–0.86, p=0.03–0.05) conferred significant protection in
the women. Stratified by menopausal status, this effect was observed in pre-menopausal women especially those whose
antioxidant intake was high (OR 0.42–0.69, p=0.04). In post-menopausal women, effect of low intake elicited susceptibility
(OR 1.19–1.67, p=0.07–0.17) to breast cancer.
Conclusions/Significance: Based on a homogeneous Caucasian population, the MPO G463A polymorphism places post-
menopausal women at risk for breast cancer, where this effect is modified by diet.
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Introduction
Myeloperoxidase (MPO) is a microbicidal enzyme secreted by
reactive neutrophilsatthesitesofinflamedorgansandtissuesduring
the phagocytosis. Upon activation MPO catalyze the formation of
powerful oxidants such as hypochlorous acid, which kills microbes.
Levels of MPO-containing neutrophils are elevated in breast
secretions as well as breast tissue with and without cancer [1,2,3].
It has been suggested that during chronic inflammation MPO is
involved in DNA adduct formation through activation of
heterocyclic amines to form chemically-reactive reactive oxygen
species (ROS) in mammary epithelial cells [4]. Although ROS have
important roles in cell signaling and homeostasis, the excess binds
and damage DNA leading to oxidative stress, peroxidation of lipids
and damage to cellular structures. In fact, inflammation and
elevated peroxidase activity have been shown to increase the risk for
women to develop breast cancer (relative risk 2.5, 95% confidence
interval [CI] 1.01–5.16) [5]. An important neutralizer of the excess
ROS is the consumption of antioxidants from fruits and vegetables.
However, epidemiologic data regarding the association between
fruit/vegetable intake and breast cancer risk were inconsistent [6].
The Long Island Breast Cancer Study Project showed that
increased consumption of fruits and vegetables, rich sources of
antioxidant nutrients which serve to reduce ROS levels, was
associated with decreased breast cancer risk among post-meno-
pausal but weaker associations among pre-menopausal women [7].
Ontheotherhand,post-menopausalwomenwithlowlevelsofMPO
activity who consumes low antioxidants sources are likely to have
increased levels of oxidative stress [8] which may significantly raise
breast cancer risk in this group [9].
A guanosine (G) to adenosine (A) nucleotide substitution,
2G463A (rs2333227), located 463 bp upstream of transcription
start site of MPO is found to have impact on the consensus
transcription factor binding sites [10]. The commonly occurring
2463G allele (frequency: ,77%) were found to elevate MPO
transcriptional activity, via promoting SP1 transcription factor
binding whereas the minor 2463A allele (frequency: ,23%) was
shown to confer ,25 times lower transcriptional activation,
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2463G allele has been associated with increased MPO activity in
several diseases [11,12] including lung cancer [13,14]. The lower
activity A allele which is associated with lower levels of polycyclic
aromatic hydrocarbons [15] and ROS production elicited
decreased risk in diseases such as coronary artery [16], Alzheimer’s
[12], multiple sclerosis [11], myeloid leukemia [17], esophageal
[18] and lung cancers [14,19,20,21]. Accumulating evidence also
suggests association of MPO-G463A with breast cancer develop-
ment although discrepancies exist.
In this study, we perform a meta-analysis to evaluate the
association between the MPO-G463A variant and risk of breast
cancer, also taking into consideration the potential modifying
influences of menopausal status, antioxidant and vitamins/
carotenoid intake of breast cancer and healthy women.
Materials and Methods
Selection of studies and genotype data
Figure 1 shows the strategy used for PubMed search as of
February 2011 yielding five articles that used Caucasians (living in
the United States [US]) [9,22,23,24,25], after excluding one study
that used Asian subjects [26]. Of the five, we also excluded another
[23] given its focus on breast cancer recurrence and survival and
not on risk. In two [9,25] of the remaining four studies,
overlapping data merited inclusion of only the most recent one
[9]. One study [24] that investigated the 2764 T.C (rs2243828)
polymorphism was also included given its 100% genotype
concordance in Caucasians (http://snp500cancer.nci.nih.gov)
with G463A polymorphism. Thus, the final number of studies
included in the meta-analysis was three [9,22,24] (Table 1). Two
investigators independently verified for each article the demo-
graphic (first author’s name, published year, country of origin,
matching criteria) and the genotype data information. Sample
sizes from these studies were derived from the genotypic data used
to calculate summary effects for the MPO G463A polymorphism.
Primary analysis and subgroups
In the main analysis, we sought effects of the MPO-G463A
polymorphism in pre-menopausal and post-menopausal women.
There were three subgroups in our meta-analysis that involved the
diet variable. One, genotypic data from the antioxidant subgroup
were based on consumption of the combination of fruits and
vegetables which were categorized as low and high. Two,
genotypic data from the vitamin/carotenoid subgroup were based
on low and high intake of vitamins C, E and carotenoids. Three,
we investigated the level of antioxidant consumption patterns in
menopausal women. In all analyses, the probability of differential
risk associations between pre-menopausal and post-menopausal
women as well as high and low consumption levels warranted
testing for presence of interactions.
Quality of studies and data analysis
Using the x
2 test, we evaluated deviation of the genotypic
frequencies of control subjects from the Hardy-Weinberg
equilibrium (HWE). While controls in Ahn et al [22] deviated
from the HWE in the primary analysis and subgroups (Tables 1, 2
and 3), those in Li et al [9] did so only under the subgroup of post-
menopausal women with low antioxidant intake (Table 3).
Assuming an odds ratio (OR) of 1.5 at a genotypic risk level of
a=0.05 (two-sided), power was considered adequate at $80%.
Statistical power of the studies was adequate for post-menopausal
but not pre-menopausal women (Table 1). As well, data for the
diet subgroup (Table 2) had adequate power to demonstrate an
association, but not in the diet-menopausal subgroup (Table 3).
All three studies [9,22,24] were matched by age. Two [9,24]
used date of blood collection and one [24] factored in menopausal
status. In all, two [9,24] of the three studies used a combination of
the above-mentioned matching criteria. All P values were two-
sided with significance set at ,0.05 except in heterogeneity
estimation. P values in the tests for interaction were corrected with
the Bonferroni analysis. Data were analyzed using the G*Power
statistical program (http://www.psycho.uni-dubeldorf.de/aap/
projects/gpower), Review Manager (RevMan 4.2; Cochrane
Collaboration) and SigmaStat 2.03.
Meta-analysis
We estimated OR and 95% CI of breast cancer associated with
variant low activity compared with common high activity using the
homozygous model (AA versus GG). We also examined the
heterozygous genotype with low versus medium+high activity
(AA versus GA+GG) as well as low+medium versus high activity
(AA+GA versus GG). These contrasts correspond to recessive and
dominant effects of the variant A allele, respectively. Finally, we
estimated OR of the variant A allele frequency assuming the risk
could differ across all three genotypes (co-dominant genetic model)
[27]. To compare the OR on the same baseline, we used crude
OR to conduct the meta-analysis. Pooled OR were obtained using
either the fixed or random effects models. Fixed-effects was used in
the absence of heterogeneity [28] while random-effects was used in
its presence [29].
To test for robustness of the summary effects, we used sensitivity
analysis which involved omitting one study at a time and
Figure 1. Summary of Literature Search.
doi:10.1371/journal.pone.0032389.g001
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estimated using the x
2-based Q test [30], significance set at
P,0.10 [31]; explored using subgroup analysis [30] with
menopausal status and diet as variables and quantified with the
I
2 statistic which measures degree of inconsistency among studies
[32]. Publication bias was not investigated because of low
sensitivity of qualitative and quantitative tests, the number of
studies being lower than ten [33].
Results
Here we investigated the breast cancer risk associated with MPO-
G463A polymorphism status in ethnically homogenous Caucasian
women. The post-menopausal (2,402 cases, 2,766 controls) and pre-
menopausal (573 cases, 661 controls) groups came from three
[9,22,24] and two studies [22,24], respectively (Table 1). Initial
meta-analysis has shown that post-menopausal women carrying the
lower transcriptional MPO activity [AA] genotype were at non-
significantly increased risk under homozygous and recessive models
(OR 1.14, p=0.35) (Table 4, Figure 2A). Under the same models,
the pre-menopausal women carrying the lower transcriptional
activity AA genotype, were found to be at significantly reduced risk
(OR 0.56–0.57, p=0.03) (Table 4, Figure 2B).
Removing the Ahn et al study [22], whose controls violated
HWE did not change these risk effects by sensitivity analysis. All
effects under menopausal status including outcomes of sensitivity
analysis (data not shown) were obtained under homogeneous
conditions (Table 4).
Table 4 shows subgroup antioxidant and carotenoid analyses
indicating significantly reduced breast cancer risk in the co-
dominant and homozygous models. This was observed in low
activity AA genotype women (regardless of menopausal status) who
consumed high levels of fruits-vegetables (OR 0.86, p=0.04 and
0.67, p=0.05). Separate analyses of fruits only and vegetables only
yielded similar results (data not shown). Likewise, similar results
were seen in such women with high levels of carotenoid intake
(OR 0.86, p=0.03 and 0.68, p=0.05). Separate analyses of
vitamins C and E yielded similar but non-significant results (data
not shown).
Table 4 shows the protective role of high antioxidant intake,
evident in the subgroup analysis by menopausal status. Thus, this
level of antioxidant intake in women who carried the low activity
AA genotype were protected from breast cancer risk, non-
significant in post-menopausal (OR 0.83–0.89, p=0.21–0.70)
but significant in pre-menopausal (OR 0.42–0.69, p=0.04)
women. The pre-menopausal findings, however, came from just
Table 1. Characteristics of the studies of MPO-G463A polymorphism and its association with breast cancer according to
menopausal status.
Pre-menopausal Post-menopausal
First Author (year) Case Control
Power=0.05
OR.1.5
maf* in
controls HWE Case Control
Power=0.05
OR.1.5
maf* in
controls HWE
Ahn (2004) 332 362 74.8 0.26 0.003 656 662 95.2 0.23 0.01
He (2009) 241 299 63.5 0.21 0.52 852 1,239 99.4 0.21 0.71
Li (2009) --- --- --- --- --- 894 865 98.7 0.28 0.06
Three studies 573 661 --- --- --- 2,402 2,766 --- --- ---
*maf: minor allele frequency; HWE: Hardy-Weinberg equilibrium.
doi:10.1371/journal.pone.0032389.t001
Table 2. Characteristics of the studies of MPO-G463A polymorphism and its association with breast cancer stratified by antioxidant
and vitamin-carotenoid intake.
First Author
(year) Case Control
Power=0.05
OR.1.5
maf* in
controls HWE Case Control
Power=0.05
OR.1.5
maf* in
controls HWE
Antioxidant intake
Low High
Ahn (2004) 519 529 90.0 0.22 0.03 474 522 88.3 0.26 0.40
He (2009) 573 764 95.1 0.20 0.76 525 781 94.3 0.20 0.70
Two studies 1,092 1,293 --- --- --- 999 1,303 --- --- ---
Carotenoid intake
Low High
Ahn (2004) 534 527 90.2 0.22 0.34 460 525 87.9 0.25 0.05
He (2009) 621 831 96.5 0.20 0.46 577 840 95.9 0.21 0.52
Two studies 1,155 1,358 --- --- --- 1,037 1,365 --- --- ---
doi:10.1371/journal.pone.0032389.t002
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consumption in post-menopausal women who carried the low
activity AA genotype were associated with increased risk in all
genetic models (OR 1.19–1.67, p values =0.07–0.17). Increased
risk, however, was not evident in pre-menopausal women with low
antioxidant intake.
Of the 32 comparisons in the primary and subgroup analyses in
which tests for heterogeneity were applied, 22 (68.8%) had none
(I
2=0%). However, none of the tests of interaction between pre-
menopausal and post-menopausal women as well as between low
and high consumption in the subgroup analyses were significant
after the Bonferroni correction treatment (Table 4).
Discussion
Menopausal Status
Our analysis has demonstrated that post-menopausal women
carrying the low activity AA genotype were associated with non-
significantly increased breast cancer risk (up to 1.1-fold) whereas
the risk associated with pre-menopausal women who carried the
low activity AA genotype was significantly protective (up to 44%).
The altered breast cancer risk observed by menopausal status may
be partly explained by the differences in age and levels of estrogen
production between pre-menopausal and post-menopausal women
[9]. Estrogen has been found to modify MPO activity levels by
influencing gene expression, monocyte number, or degree of MPO
release, potentially altering serum levels [34,35,36]. Estradiol levels
was also shown to modulate the circulating MPO levels during the
menstrual cycle [37]. More importantly, estrogen has been shown
to differentially regulate MPO expression according to genotype
[12].
A recent meta-analysis [38], which investigated risk associated
with MPO-G463A polymorphism regardless of the menopausal
status and ethnic background [22,25,26] reported no association
with breast cancer. The strengths of our study include (a) ethnic
(,95% Caucasian) and geographical (USA) homogeneity; (b) the
statistically significant pooled findings which were homogeneous
(Pheterogeneity=0.10–0.78) and (c) a substantial number of cases and
controls were pooled from the studies, which significantly
increased the statistical power of the analysis.
Antioxidant Intake and Menopausal Status
An important modifier in the relationship between MPO
genotype and breast cancer risk is consumption of fruits and
vegetables. It has been shown that post-menopausal women with
reduced levels of MPO activity who consume low antioxidants are
likely to have increased levels of oxidative stress [8] which may
significantly raise breast cancer risk [9]. Our findings also support
this as the non-significantly increased risk effects of the post-
menopausal women became significant (up to 1.7-fold) when they
consumed low levels of antioxidants. On the other hand, post-
menopausal women with low activity MPO genotype were found
to be associated with statistically significant protective risk when
they consumed high level of antioxidants. The analysis of
antioxidant effects in pre-menopausal women have shown
statistically significant protective effects (24–56%, up to
p=0.001) in all genetic models with high consumption of
antioxidants, although these findings are based on one study.
The relatively small sample size, particularly in the pre-
menopausal group, may increase the likelihood of Type I error
meriting caution regarding interpretation of its outcomes. The
antioxidant intake data from two studies [9,24] was collected prior
to development of breast cancer, therefore misclassification bias
between cases and controls is unlikely to affect the risk estimates.
Gene-gene interactions
The modifying influences of diet, age and menopausal status are
best considered in context of other genes in the oxidative stress
pathway. Two studies in our analysis investigated the MPO-G463A
polymorphism in concert with the variants of other antioxidant
enzymes, including catechol-O-methyltransferase (COMT) [24],
endothelial nitric oxide synthase (NOS3) heme-oxygenase-1 (HO-1)
and catalase (CAT) [9]. Study-specific [24] joint effects of COMT
and MPO was marginally protective (OR 0.28, 95% CI 0.08–
1.00). In addition, the CAT-MPO combination may greatly
decrease the hazard of death from breast cancer [39]. Available
data on joint effects was not sufficient to allow further analysis of
gene-gene interactions.
Conclusion
Our meta-analysis implicates that menopausal status and intake
of antioxidants modified the risk associated with breast cancer risk
of women who carried the low activity AA genotype of MPO-
G463A polymorphism. The non-significantly increased risk
associated with post-menopausal women became highly significant
when they consumed low levels of antioxidants. On the other
hand, pre-menopausal women with the same lower activity
genotype were at protective risk, which became more protective
when they used high levels of antioxidants. Our findings suggest
Table 3. Characteristics of the studies of MPO-G463A polymorphism and its association with breast cancer stratified by
menopausal status and antioxidant intake.
First Author (year) Case Control
Power=0.05
OR.1.5
maf* in
controls HWE Case Control
Power=0.05
OR.1.5
maf* in
controls HWE
Antioxidant Intake
Low in pre-menopausal High in pre-menopausal
Ahn (2004) 150 180 43.8 0.24 0.05 174 176 46.2 0.27 0.03
Low in post-menopausal High in post-menopausal
Ahn (2004) 372 338 75.7 0.2 0.52 274 315 67.6 0.26 0.87
Li (2009) 216 195 52.4 0.19 0.03 194 198 50.6 0.22 0.14
Two studies 588 533 --- --- --- 468 513 --- --- ---
doi:10.1371/journal.pone.0032389.t003
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Updated 21 Nov 2011
Transcription
Activity OR (95% CI) P value Phet I
2 OR (95% CI) P value Phet I
2 Pinteraction*
N (cases/controls) N (cases/controls)
Menopausal Status
Premenopausal 2 (573/661) Postmenopausal 3 (2,402/2,766)
A vs G per allele effect 0.88 (0.72–1.06) 0.19 0.31 5 1.01 (0.95–1.12) 0.77 0.54 0 .1
AA vs GG low versus high 0.56 (0.34–0.94) 0.03 0.93 0 1.14 (0.87–1.49) 0.36 0.34 7 0.32
AA vs GA+GG low versus
medium+high
0.57 (0.34–0.93) 0.03 0.99 0 1.14 (0.87–1.48) 0.34 0.38 0 0.36
AA+GA vs GG low+medium versus
high
0.94 (0.75–1.19) 0.62 0.34 0 1.02 (0.91–1.15) 0.68 0.31 14 .1
Antioxidants Only
Low 2 (1,092/1,293) High 2 (999/1,303)
A vs G per allele effect 1.04 (0.91–1.20) 0.56 0.94 0 0.86 (0.74–0.99) 0.04 0.10 62 .1
AA vs GG low versus high 1.05 (0.73–1.51) 0.80 0.95 0 0.67 (0.45–1.01) 0.06 0.78 0 .1
AA vs GA+GG low versus
medium+high
1.03 (0.72–1.48) 0.87 0.95 0 0.70 (0.47–1.06) 0.09 0.97 0 .1
AA+GA vs GG low+medium versus
high
1.05 (0.89–1.25) 0.54 0.96 0 0.89 (0.75–1.05) 0.17 0.11 61 .1
Carotenoids
Low 2 (1,155/1,358) High 2 (1,037/1,365)
A vs G per allele effect 1.05 (0.92–1.20) 0.48 0.96 0 0.86 (0.75–0.99) 0.03 0.14 55 0.88
AA vs GG low versus high 1.01 (0.70–1.47) 0.94 0.52 0 0.68 (0.46–1.00) 0.05 0.53 0 .1
AA vs GA+GG low versus
medium+high
0.99 (0.69–1.42) 0.96 0.47 0 0.71 (0.49–1.05) 0.09 0.66 0 .1
AA+GA vs GG low+medium versus
high
1.08 (0.91–1.26) 0.38 0.80 0 0.86 (0.73–1.01) 0.07 0.15 52 0.93
Menopausal Status and Antioxidants
Premenopausal
Low antioxidants 1 (450/180) High antioxidants 1 (174/176)
A vs G per allele effect 0.99 (0.69–1.42) 0.95 ----- ----- 0.69 (0.49–0.98) 0.04 ----- ----- .1
AA vs GG low versus high 0.74 (0.31–1.78) 0.51 ----- ----- 0.42 (0.18–0.97) 0.04 ----- ----- .1
AA vs GA+GG low versus
medium+high
0.70 (0.30–1.65) 0.42 ----- ----- 0.42 (0.18–0.97) 0.04 ----- ----- .1
AA+GA vs GG low+medium versus
high
1.08 (0.70–1.68) 0.73 ----- ----- 0.42 (0.18–0.97) 0.04 ----- ----- 0.98
Postmenopausal
Low antioxidants 2 (588/533) High antioxidants 2 (468/513)
A vs G per allele effect 1.21 (0.99–1.48) 0.07 0.77 0 1.06 (0.86–1.30) 0.60 0.83 0 .1
AA vs GG low versus high 1.67 (0.96–2.88) 0.07 0.86 0 0.83 (0.46–1.51) 0.54 0.25 24 .1
AA vs GA+GG low versus
medium+high
1.61 (0.94–2.76) 0.08 0.91 0 0.89 (0.49–1.61) 0.70 0.34 0 .1
AA+GA vs GG low+medium versus
high
1.19 (0.93–1.51) 0.17 0.31 3 0.85 (0.66–1.09) 0.21 0.13 57 .1
OR (95% CI): odds ratio 95% confidence interval; Phet: P value for heterogeneity; Given that all P values for the heterogeneity test were .0.10, the fixed-effects model
was used;
*Bonferroni-corrected.
doi:10.1371/journal.pone.0032389.t004
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activity. Future studies with larger sample sizes particularly among
pre-menopausal women may shed light on complexities of the
many pathways involved in oxidative stress and breast cancer
development, providing hypotheses for future functional studies.
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